Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Heart failure in 2015

Better results from prevention than from additional treatment

Nature Reviews Cardiology volume 13, pages 75–77 (2016)Cite this article

Subjects

In 2015, success in clinical trials in heart failure was obtained mainly from prevention, whereas treatments showed neutral or even adverse effects. A new glucose-lowering medication prevents development of heart failure. Treating central sleep apnoea might be harmful. In Chagas cardiomyopathy, benznidazole treatment did not affect long-term clinical outcomes.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Effects of SGLT2 inhibitors.

References

  1. Levy, P. et al. Prevalence and impact of central sleep apnea in heart failure. Sleep Med. Clin. 2, 615–621 (2007).

    Article  Google Scholar 

  2. Cowie, M. R. et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N. Engl. J. Med. 373, 1095–1105 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).

    Article  CAS  PubMed  Google Scholar 

  4. Green, J. B. et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 373, 232–242 (2015).

    Article  CAS  PubMed  Google Scholar 

  5. Pfeffer, M. A. et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373, 2247–2257 (2015).

    Article  CAS  PubMed  Google Scholar 

  6. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 373, 2103–2116 (2015).

  7. Fabbro, D. L. et al. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev. Soc. Bras. Med. Trop. 40, 1–10 (2007).

    Article  PubMed  Google Scholar 

  8. Morillo, C. A. et al. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. N. Engl. J. Med. 373, 1295–1306 (2015).

    Article  CAS  PubMed  Google Scholar 

  9. de Andrade, A. L. et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348, 1407–1413 (1996).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lars Køber is at the Department of Cardiology, the Heart Centre, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark.,

    Lars Køber

Authors
  1. Lars Køber
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Lars Køber.

Ethics declarations

Competing interests

The author has received honoraria as a speaker for Novartis and Servier.

Related links

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Køber, L. Better results from prevention than from additional treatment. Nat Rev Cardiol 13, 75–77 (2016). https://doi.org/10.1038/nrcardio.2015.205

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrcardio.2015.205

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing